Which anti-VEGF treatment regimen?

Intravitreal anti-vascular endothelial growth factor agents, such as aflibercept, ranibizumab, and bevacizumab, have revolutionised the way neovascular retinal diseases are managed. However, there are still questions about the most effective dosing schedule for these medications to help optimise treatment effect and patient experience. Here, Sebastian Wolf highlights the key differences between the most commonly used dosing schedule.

[@sarahmccoy1941]

What is needed is for pharmaceutical companies to develop an anti-VEGF drug that can be delivered as drops instead of injections.